194 related articles for article (PubMed ID: 15223097)
1. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial.
Assadi SM; Hafezi M; Mokri A; Razzaghi EM; Ghaeli P
J Subst Abuse Treat; 2004 Jul; 27(1):75-82. PubMed ID: 15223097
[TBL] [Abstract][Full Text] [Related]
2. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
4. Induction of patients with moderately severe methadone dependence onto buprenorphine.
Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
6. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
[TBL] [Abstract][Full Text] [Related]
7. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
De S; Jain R; Ray R; Dhawan A; Varghese ST
Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
[TBL] [Abstract][Full Text] [Related]
9. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.
Soeffing JM; Rastegar DA
J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
[TBL] [Abstract][Full Text] [Related]
11. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
12. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
13. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.
Herman I; Shamir D; Bar-Hamburger R; Pick CG; Schreiber S
Addict Behav; 2005 Jul; 30(6):1154-67. PubMed ID: 15925125
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
16. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
[TBL] [Abstract][Full Text] [Related]
18. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial.
Raistrick D; West D; Finnegan O; Thistlethwaite G; Brearley R; Banbery J
Addiction; 2005 Dec; 100(12):1860-7. PubMed ID: 16367987
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
Simojoki K; Lillsunde P; Lintzeris N; Alho H
Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
